BiotechTube
Microbiotica

Microbiotica

Cambridge, United Kingdom· Est.
microbiotica.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $117.5M

Overview

Microbiotica is a UK-based, clinical-stage biotech translating microbiome science into defined live biotherapeutic medicines. Founded in 2016 as a spin-out from the Wellcome Sanger Institute, the company has raised £62M to date and is advancing two lead clinical programs: MB097 for enhancing immunotherapy in melanoma and MB310 for ulcerative colitis. Its core strength is a precision microbiome profiling platform that identifies bacterial signatures from clinical data to develop targeted therapies for specific patient populations.

Immuno-oncologyInflammatory Bowel Disease

Technology Platform

Proprietary clinic-led microbiome discovery platform utilizing anaerobic culturing, bioinformatics, and machine learning to identify specific bacterial strains linked to clinical outcomes and enable development of defined Live Biotherapeutic Products (LBPs).

Funding History

2
Total raised:$117.5M
Series B$67.5M
Series A$50M

Opportunities

Large and growing markets in immuno-oncology (improving checkpoint inhibitor response) and inflammatory bowel disease, where significant unmet need exists.
The precision medicine approach, pairing defined LBPs with biomarker-stratified patients, could command premium pricing and improve clinical success rates.

Risk Factors

Clinical and regulatory risk inherent in a novel therapeutic modality; the complex science of microbiome-host interactions may not translate predictably in later-stage trials.
Competitive and commercial risk from other microbiome companies and the challenge of establishing reimbursement for new LBP drug classes.

Competitive Landscape

Competes with other microbiome-focused biotechs (e.g., Seres Therapeutics, Vedanta Biosciences) and large pharma companies exploring microbiome modulators. Differentiation lies in its precision, clinic-led platform from the Wellcome Sanger Institute, focusing on defined bacterial consortia with known mechanisms for specific patient segments.

More companies in United Kingdom →